“Should Oral Contraceptives Be Available Over the Counter?” is the timely topic addressed by Britt Whalin, AM (Director of Development and Communications), Kate Grindlay, MSc (Senior Pr...read more

The Food and Drug Law Institute, the premier educational organization in the field of food and drug law, announced today that President and Chief Executive Officer Susan C. Winckler will step down ...read more

FDA’s Social Media Draft Guidance Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on February 2014 by Davina Rosen Marano, Editor, FDLI

“Do We ‘Like’ FDA’s ‘First Social Media Guidance’ or is it Nothing to ‘Tweet’ About?” is the timely topic addressed by Daniel Kracov, Partner, ...read more

“Ravioli Trees and Tortellini Bushes: What Should Courts Expect from the Reasonable Consumer When it Comes to ‘Natural’ Claims?” is the timely topic addressed by John E. Vil...read more

“The Need for Clarity: Where Should FDA Focus Its Resources When Implementing the Compounding Provisions of the Drug Quality and Security Act?” is the topic addressed by Karla L. Palmer...read more

FDA’s Postmarket Surveillance of Medical Devices Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on December 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

“Is FDA’s Decision to Ramp-up the Postmarket Surveillance of Medical Devices the Best Way to Make Devices Safe?” is the topic addressed by Thomas R. McLean, M.D., J.D., FACS and Alexander B. McLean...read more

The Harmonization of Cosmetics Standards Is Focus of New FDLI Food and Drug Law Policy Forum

Posted on December 2013 by Michael Levin-Epstein, Editor-in-Chief, FDLI

“Is It Time for Harmonized Cosmetics Standards? A Comparison of U.S. and E.U. Cosmetics Regulation” is the topic addressed by Kimberly K. Egan, Founder, Saltbox Consulting and Jennifer ...read more

The Food and Drug Law Institute To Honor Axelrad, Gibbs, Holcombe, Kingham

Posted on December 2013 by Michel Levin-Epstein, Editor-in-Chief, FDLI

Honorees Will Receive Distinguished Service and Leadership Awards at Holiday Reception December 10 December 5, Washington, DC -- The Food and Drug Law Institute will honor four outstanding food and...read more

“How Should FDA and Generic Drug Manufacturers’ Respond to FDA’s Proposed Changes to Generic Drug Labeling Rules?” is the topic addressed by Jane Bockus, Shareholder, Cox Sm...read more

“With Respect to New Molecular Entities with Abuse Potential, Should FDA’s Recommendations for Controlled Substances Act (CSA) Scheduling Be Immediately Effective upon FDA Approval?&rdq...read more